US Capitol Capsule: Will PDUFA V be a 'damned if it does, damned if it doesn't' scenario for FDA?
This article was originally published in Scrip
Instead of being praised for speeding new treatments to patients or advancing medical innovation, the US FDA has increasingly come under sharp criticism for failing to do enough to ensure patient safety, which has resulted in the agency shifting to a more cautious, risk-averse posture in recent years, asserted Jonathan Leff, managing director of New York-based equity investment firm Warburg Pincus.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.